Hormone therapy is one of the fastest-growing categories in outpatient medicine, and also one of the most commonly mismarketed. Most clinics run a single campaign for what are actually two very different patient populations. Here's the playbook that actually works for both.
Hormone therapy marketing fails most often because clinics run a single undifferentiated campaign for what are actually two distinct patient populations with completely different search behavior. The women's HRT patient, typically 40 to 65, researches perimenopause and menopause symptoms first ("why am I so tired all the time," "perimenopause symptoms at 45") and discovers hormone therapy as a solution second. The male TRT patient, typically 30 to 55, searches more directly for the treatment itself ("low testosterone clinic near me," "TRT cost").
Running both audiences through one generic "hormone clinic" campaign and landing page dilutes messaging for both. Splitting into separate campaigns, separate ad copy, separate landing pages, consistently improves conversion rate and lowers cost per lead for both patient types.
For the women's HRT audience, the highest-performing content leads with symptoms, not treatment. A page titled "Why Am I So Exhausted? Perimenopause Symptoms Explained" that naturally transitions into hormone therapy as a solution captures search volume that a page titled "Bioidentical Hormone Therapy" never sees, because far more women search symptoms than search the clinical term.
For the TRT audience, direct service-page content performs better because male patients researching low testosterone tend to already know the treatment name and are comparing providers on cost, process, and credibility rather than researching the underlying condition from scratch.
Testosterone is a controlled substance, and Google's healthcare advertiser policies apply specific restrictions to prescription drug advertising. The safe and effective approach centers campaigns on the clinical service and consultation, "testosterone replacement therapy consultation," "menopause hormone specialist," rather than making direct treatment claims or naming specific medications in ad copy. This keeps campaigns policy-compliant while still capturing the high-intent searches driving the category.
Compounded bioidentical hormones carry their own regulatory considerations that vary by state. Working with a marketing partner who understands these constraints, rather than one who builds generic campaigns and risks disapproval or enforcement action, matters more in this category than almost any other cosmetic or wellness specialty.
National telehealth hormone platforms compete directly with local clinics for the same patient searches, often with lower advertised prices driven by scale. The local clinic's genuine, defensible advantage is what telehealth cannot replicate: in-person lab draws, same-day dose adjustments when side effects appear, and an ongoing physician relationship that catches problems an online intake form misses.
Marketing that makes this advantage concrete, rather than a vague "personalized care" claim, converts better against telehealth competition. Content and ad copy that specifically says "we adjust your dose in person based on your labs, not a generic algorithm" consistently outperforms generic hormone clinic messaging in head-to-head testing.
See real results: Medical practice case studies →